Adalimumab (Humira) in the Treatment of Psoriasis

• Adalimumab is a monoclonal antibody against TNF. It is currently approved for the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis.
• Dosing is 40 mg subcutaneously every other week.
• Phase III trial results showed excellent results in the treatment of psoriasis. There has also been a recent placebo controlled trial presented comparing methotrexate to adalimumab. This revealed a significant advantage with adalimumab.
• Patients may develop an injection site reaction with adalimumab. Serious reactions include serious infections (including tuberculosis), demyelinating disease, bone marrow suppression, and an increased incidence of malignancy.

Kalb. R 2013 (07) – Kalb. R. Treatment of Psoriasis in the Age of Biologics – 25th Annual Scientific Meeting of the Dermatological Society of Singapore (DSS) – Singapore